Arca
Skip to content
Tools
Tools

Warning Letter to King Bio Inc.

Unspecified. See King Bio's company page or this site's inspections.

On Jan 11, 2018, FDA's CDER sent King Bio Inc. a warning letter citing unapproved new drug, marketing claims, labeling.

  • Letter date: Jan 11, 2018
  • Issued by: CDER
  • Closeout: —

The Letter

As posted on FDA.gov ↗; cited 21 CFR sections link to their page.

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION SILVER SPRING, MD 20993

• “Homeopathy to Beat Addiction”

• “A natural aid to help provide recovery, restoration or relief from the symptoms of overconsumption of alchols [ sic ] and other drugs”

• “[D]iminish cravings and desires....”

Recent Letters Citing Unapproved new drug

See them all

Record

Recipient
Dr. Frank J. King, Jr.
FDA site ID (FEI)
1053442

Tags are assigned by Arca from the letter's text. A closeout letter means FDA found the firm's corrections adequate; no closeout does not mean the issues are unresolved. FDA warning letters

Esc

Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.